Pantoprazole: A proton pump inhibitor

Clinical Drug Investigation

Volumn 29, Issue SUPPL. 2, 2009, Pages 3-12

  Dias, Luis Moreira ^a  

^a Médico Gastroenterologista   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; HUMAN; PEPTIC ULCER; RECURRENT DISEASE; REVIEW;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DRUG INTERACTIONS; GASTROESOPHAGEAL REFLUX; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; RECURRENCE;

EID: 77949327540     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1153121-s0-000000000-00000     Document Type: Review

References (54)

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006 Aug; 101 (8): 1900-20; quiz 1943
2. Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs 2008; 68 (7): 925-47
3. Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 2004; 64 (3): 277-95
4. Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009; 69 (1): 51-69
5. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63 (24): 2739-54
6. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244
7. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006; 3: CD002095
8. Rostom A, Dube C, Wells G, et al. Prevention of NSAIDinduced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; (4): CD002296
9. Cheer SM, Prakash A, Faulds D, et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63 (1): 101-33
10. Kromer W, Kruger U, Huber R, et al. Differences in pHdependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998 Feb; 56 (2): 57-70
11. Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002 Nov; 123 (5): 1588-97
12. Kearns GL, Blumer J, Schexnayder S, et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol 2008 Nov; 48 (11): 1356-65
13. Protonix- (pantoprazole sodium) US prescribing information. Philadelphia (PA): Wyeth Pharmaceuticals, 2008.
14. Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44 (5): 441-66
15. Ferron GM, Paul JC, Fruncillo RJ, et al. Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. J Clin Pharmacol 1999 Sep; 39 (9): 945-50
16. Lorf T, Ramadori G, Ringe B, et al. Pantoprazole does not affect cyclosporin A blood concentration in kidneytransplant patients. Eur J Clin Pharmacol 2000 Jan; 55 (10): 733-5
17. Lorf T, Ramadori G, Ringe B, et al. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol 2000 Aug; 56 (5): 439-40
18. Koch HJ, Hartmann M, Bliesath H, et al. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Int J Clin Pharmacol Ther 1996 Oct; 34 (10): 420-3
19. Ehrlich A, Fuder H, Hartmann M, et al. Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol 1996; 51 (3-4): 277-81
20. Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995 Jun; 39 (6): 700-3
21. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29 (9): 769-84
22. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997 Jun; 112 (6): 1798-810
23. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan; 100 (1): 190-200
24. Bardhan KD, Achim A, Riddermann T, et al. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastrooesophageal reflux disease. Aliment Pharmacol Ther 2007 Jun 15; 25 (12): 1461-9
25. Bardhan KD, Van Rensburg C. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001 Oct; 15 (10): 1585-91
26. Gillessen A, Beil W, Modlin IM, et al. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004 Apr; 38 (4): 332-40
27. Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005 Nov 1; 22 (9): 803-11
28. Dupas JL, Houcke P, Samoyeau R. Pantoprazole versus lansoprazole in French patients with reflux esophagitis. Gastroenterol Clin Biol 2001 Mar; 25 (3): 245-50
29. Korner T, Schutze K, van Leendert RJ, et al. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion 2003; 67 (1-2): 6-13
30. Nayar DS, Vaezi MF. Classifications of esophagitis: who needs them? Gastrointest Endosc 2004 Aug; 60 (2): 253-7
31. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 Aug; 45 (2): 172-80
32. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003 Sep 15; 18 (6): 587-94
33. Glatzel D, Abdel-Qader M, Gatz G, et al. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion 2006; 74 (3-4): 145-54
34. Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; (2): CD003245
35. Escourrou J, Deprez P, Saggioro A, et al. Maintenance therapy with pantoprazole 20mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999 Nov; 13 (11): 1481-91
36. Goh KL, Benamouzig R, Sander P, et al. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial-the EMANCIPATE study. Eur J Gastroenterol Hepatol 2007 Mar; 19 (3): 205-11
37. Metz DC, Bochenek WJ. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther 2003 Jan; 17 (1): 155-64
38. Plein K, Hotz J, Wurzer H, et al. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 2000 Apr; 12 (4): 425-32
39. Richter JE, Fraga P, Mack M, et al. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther 2004 Sep 1; 20 (5): 567-75
40. Mossner J, Koop H, Porst H, et al. One-year prophylactic efficacy and safety of pantoprazole in controlling gastrooesophageal reflux symptoms in patients with healed reflux oesophagitis. Aliment Pharmacol Ther 1997 Dec; 11 (6): 1087-92
41. Van Rensburg CJ, Honiball PJ, Van Zyl JH, et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year followup. Aliment Pharmacol Ther 1999 Aug; 13 (8): 1023-8
42. Lauritsen K, Jaup B, Carling L, et al. Comparable efficacy of pantoprazole and omeprazole to prevent relapse in patients with GERD [Abstract]. Gut 2000; 47 Suppl. III: 60
43. Brown GJ, Yeomans ND. Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: the role of proton pump inhibitors. Drug Saf 1999 Dec; 21 (6): 503-12
44. Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007 Feb; 132 (2): 498-506
45. Bianchi Porro G, Lazzaroni M, Imbesi V, et al. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo- controlled, double-blind, parallel-group study. Dig Liver Dis 2000 Apr; 32 (3): 201-8
46. Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 2006 Aug; 101 (8): 1747-55
47. Stupnicki T, Dietrich K, Gonzalez-Carro P, et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003; 68 (4): 198-208
48. Tafuri G, Trotta F, Leufkens HG, et al. Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. Eur J Clin Pharmacol 2009 Feb; 65 (2): 209-16
49. Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003; 5 (1): 25-40
50. Madrazo-de la Garza A, Dibildox M, Vargas A, et al. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr 2003 Feb; 36 (2): 261-5
51. Tolia V, Bishop PR, Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006 Apr; 42 (4): 384-91
52. Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila) 2006 Oct; 45 (8): 741-9
53. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000 May; 6 (9 Suppl.): S491-505
54. Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf 2003; 26 (2): 121-32